GKOS Glaukos Corporation
162.70USD-0.80%Mkt Cap: 9.67B $P/E: —Today
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It off…
Industry Peers
Medical DevicesKey Statistics
Company
Market Cap9.67B USD
Enterprise Value9.48B USD
Revenue (TTM)612.84M USD
Gross Profit282.76M USD
Net Income (TTM)-187.69M USD
Revenue/Share10.58 USD
Last Price162.70 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.1K
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)323.70
PEG—
EV/EBITDA-255.92
EV/Revenue15.46
P/S15.76
P/B14.12
EPS (TTM)-3.26
EPS (Forward)0.51
52W Range
73.1677% of range190.06
52W High190.06 USD
52W Low73.16 USD
Profitability
Gross Margin55.72%
Oper. Margin-8.49%
EBITDA Margin-6.04%
Profit Margin-36.99%
ROE-28.60%
ROA-21.01%
Growth
Revenue Growth49.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.79M USD
CapEx (TTM)24.27M USD
FCF Margin2.52%
FCF Yield0.16%
Net Debt-178.62M USD
Net Debt/EBITDA4.82
Balance Sheet
Debt/Equity0.16
Current Ratio5.04
Quick Ratio4.16
Book Value/Sh11.60 USD
Cash/Share4.86 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)198.69 USD
Upside (mean)+22.1%
Target Range172.00 USD – 225.00 USD
172.00+22.1% to mean225.00
# Analysts13
Ownership
Shares Out.58.98M
Float56.83M
Insiders3.58%
Institutions105.08%
Short Interest
Short Ratio6.4d
Short % Float8.55%
Short % Out.7.06%
Shares Short4.17M
Short (prev mo.)3.95M
Technical
SMA 50171.99 (-5.4%)
SMA 200135.03 (+20.5%)
Beta0.77
S&P 52W Chg14.58%
Avg Vol (30d)754.24K
Avg Vol (10d)913.70K
Technical Indicators
RSI (14)47.6
MACD-2.9762
MACD Signal-3.4102
MACD Hist.+0.4340
BB Upper180.56 USD
BB Middle164.52 USD
BB Lower148.47 USD
BB Width19.50%
ATR (14)6.246 USD
Vol Ratio (20d)0.95x